Isolation and characterization of a hyperbranched proteoglycan from Ganoderma Lucidum for anti-diabetes

Pan, Deng; Wang, Linqiang; Chen, Congheng; Hu, Bingwen; Zhou, Ping

doi:10.1016/j.carbpol.2014.09.051

Cited by 58 publications

(32 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The mystery of G. lucidum aroused widespread interest of researchers in modern times. G. lucidum was demonstrated to possess activities including anti-cancer (Sliva, 2006 ; Rios et al, 2012 ; Boh, 2013 ; Gill et al, 2016 ), antidiabetic (Chang et al, 2015 ; Ma et al, 2015 ; Pan et al, 2015 ), hepatoprotective (Ha do et al, 2013 ; Li et al, 2013 ; Wu et al, 2016 ), antiviral (especially anti-HIV activities; Min et al, 1998 ), and immunomodulating (Wang et al, 2014a , b ). The anti-cancer of G. lucidum research is very popular in recent decades.…”

Section: Introductionmentioning

confidence: 99%

Anti-tumor and Anti-angiogenic Ergosterols from Ganoderma lucidum

et al. 2017

View full text Add to dashboard Cite

This study was carried out to isolate chemical constituents from the lipid enriched fraction of Ganoderma lucidum extract and to evaluate their anti-proliferative effect on tumor cells and human umbilical vein endothelial cells (HUVECs). Ergosterol derivatives (1–14) were isolated and purified from the lipid enriched fraction of G. lucidum. Their chemical structures were established by spectroscopic analyses or by comparison of mass and NMR spectral data with those reported previously. Amongst, compound 1 was purified and identified as a new one. All the compounds were evaluated for their anti-proliferative effect on human tumor cells and HUVECs in vitro. Compounds 9–13 displayed inhibitory activity against two types of human tumor cells and HUVECs, which indicated that these four compounds had both anti-tumor and anti-angiogenesis activities. Compound 2 had significant selective inhibition against two tumor cell lines, while 3 exhibited selective inhibition against HUVECs. The structure–activity relationships for inhibiting human HepG2 cells were revealed by 3D-QASR. Ergosterol content in different parts of the raw material and products of G. lucidum was quantified. This study provides a basis for further development and utilization of ergosterol derivatives as natural nutraceuticals and functional food ingredients, or as source of new potential antitumor or anti-angiogenesis chemotherapy agent.

show abstract

Section: Introductionmentioning

confidence: 99%

Anti-tumor and Anti-angiogenic Ergosterols from Ganoderma lucidum

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Since then, fungi have been used as traditional Chinese medicines for the prevention or treatment of various chronic diseases [1, 2]. As research on the chemical constituents of these medicinal or edible fungi has increased, there is pre-clinical evidence for G. lucidum in an array of settings including cancer treatment [3–6], diabetic control [7–9], hepato-protection [10–13], antiviral treatment [14], and immune-modulation [15, 16]. …”

Section: Introductionmentioning

confidence: 99%

Cytotoxic lanostane-type triterpenoids from the fruiting bodies ofGanoderma lucidumand their structure-activity relationships

Chen

Yong

et al. 2016

Oncotarget

View full text Add to dashboard Cite

We conducted a study of Ganoderma lucidum metabolites and isolated 35 lanostane-type triterpenoids, including 5 new ganoderols (1-5). By spectroscopy, we compared the structures of these compounds with known related compounds in this group. All of the isolated compounds were assayed for their effect against the human breast carcinoma cell line MDA-MB-231 and hepatocellular carcinoma cell line HepG2. Corresponding three-dimensional quantitative structure–activity relationship (3D-QSAR) models were built and analyzed using Discovery Studio. These results provide further evidence for anti-cancer constituents within Ganoderma lucidum, and may provide a theoretical foundation for designing novel therapeutic compounds.

show abstract

“…In recent decades, ROS has been identied to be a major factor in the development of T2DM by inactivating signaling pathway from insulin receptor to glucose transporter, and overproduction of ROS may induce apoptosis of islet b cells. 7 FYGL was demonstrated to be a neutral hyperbranched proteoglycan consisting of 4 saccharides and 17 amino acids, 17 the reductive sugars of FYGL including glucose and galactose might play an important role in ameliorating ROS level. 5 Our previous work Fig.…”

Section: The Mechanism Of Fygl Decreasing Ros and Increasing Atpmentioning

confidence: 99%